Výsledky vyhledávání - "Ivan, Houisse"

The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (

Autor: Fredrik O L, Nilsson, Peter, Gal, Ivan, Houisse, Jasmina I, Ivanova, Sandra T, Asanin

Publikováno v: Journal of medical economics. 24(1)

Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) over chemotherapy inA partitioned survival model was developed with three health states: progression-free, post-progression, and death. Progr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0939aaa84aafb93648dcf985f875ed04
https://pubmed.ncbi.nlm.nih.gov/33754924

Zobrazit plný text záznamu

The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden

Autor: Fredrik Nilsson, Sandra T. Asanin, Jasmina I Ivanova, Peter Gal, Ivan Houisse

Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) over chemotherapy in EGFR mutation-positive (EGFRm) non-small-cell lung cancer (NSCLC) has been demonstrated in clinical trials, the optimal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83da86bedfd371ac4abfe98d67a23c98

Zobrazit plný text záznamu

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

Autor: Ivan Houisse, Sumeet Panjabi, Ágnes Benedict, Istvan Majer, Marco Campioni, Sikander Ailawadhi, Andrzej Jakubowiak

Publikováno v: Expert Review of Hematology. 10:1107-1119

We assessed the economic value of carfilzomib 56 mg/mCost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02b7c91c361b20b5481dfa789a11123
https://doi.org/10.1080/17474086.2017.1391088

Zobrazit plný text záznamu

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

Autor: Sumeet Panjabi, Andrzej Jakubowiak, Eszter Tichy, Ivan Houisse, Marco Campioni, Sanjay K. Aggarwal, Beth Barber, Ágnes Benedict, Andromachi Giannopoulou

Publikováno v: Journal of Medical Economics. 19:1061-1074

To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdba37594228dd87a10897df8609e93b
https://doi.org/10.1080/13696998.2016.1194278

Zobrazit plný text záznamu

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Autor: Andrzej Jakubowiak, Sumeet Panjabi, Istvan Majer, Ivan Houisse, Marco Campioni, Sikander Ailawadhi, Agnes Benedict

Publikováno v: Blood. 128:3582-3582

Background : Carfilzomib is an innovative second generation proteasome inhibitor (PI) that binds irreversibly and selectively to the proteasome. Carfilzomib exhibits sustained inhibition of the proteasome with minimal off-target activity. Kd was appr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9370fc9517ad806f4d90baeeecd82e65
https://doi.org/10.1182/blood.v128.22.3582.3582

Zobrazit plný text záznamu

Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM)

Autor: Sanjay K. Aggarwal, Andromachi Giannopoulou, Andrzej Jakubowiak, Rafael Fonseca, Marco Campioni, Sumeet Panjabi, Ivan Houisse, Agnes Benedict

Publikováno v: Journal of Clinical Oncology. 34:8021-8021

8021Background: In ASPIRE, KRd achieved superior progression free survival (PFS) (HR = 0.69; p = 0.0001) and improved quality of life (QoL) (p < 0.001) over Rd in patients (pts) with R/RMM. We asse...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11c11e4413554cd211066605e6f43ec5
https://doi.org/10.1200/jco.2016.34.15_suppl.8021

Zobrazit plný text záznamu

Optimizing early detection of avian influenza H5N1 in backyard and free-range poultry production systems in Thailand

Autor: Saraya Tavornpanich, François Roger, Angus Cameron, Flavie Goutard, Ivan Houisse, Karoon Chanachai, Mathilde Paul, Weerapong Thanapongtharm, Katharina D.C. Stärk

Publikováno v: Preventive Veterinary Medicine
Preventive Veterinary Medicine, Elsevier, 2012, 105 (3), pp.223-234

1st International Conference on Animal Health Surveillance (ICAHS); International audience; For infectious diseases such as highly pathogenic avian influenza caused by the H5N1 virus (A/H5N1 HP), early warning system is essential. Evaluating the sens

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88b0e222ba1c31cdb92a8981cef6a153
https://hal.inrae.fr/hal-02642634

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání